Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena

This article was originally published in The Tan Sheet

Executive Summary

Investment analysts are confident in Johnson & Johnson's long-term viability even though recalls of OTC drugs and the temporary closure of the facility where the products were made prompted the firm to slash full-year profits estimates and triggered a federal investigation

Related Content

J&J Separates U.S. OTCs In "Unorthodox" Reorg To Get McNeil Back On Track
J&J Consumer Unit Underperforms In Q3 As Recall Aftereffects Linger
J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
J&J Delivers No Evidence FDA Knew Of "Phantom" Recall - Congressional Staff
Business News In Brief
States subpoena J&J information
J&J Keeps Expectations Conservative For OTC Manufacturing Remediation
FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912
FDA Questions J&J/Merck OTC Joint Venture's Manufacturing Practices
Consumer Lawsuits Allege J&J Concealed OTC Defects





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts